• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nextrials Sees Latest Trial as the Future of EDC

Nextrials Sees Latest Trial as the Future of EDC

May 27, 2009
CenterWatch Staff

Electronic data capture (EDC) company Nextrials is conducting a multisite trial that CEO James Rogers views as the future of clinical trials and possibly of his company.

The six-site trial, conducted with electronic health record (EHR) vendor Greenway Medical Technologies, is the first trial to collect data from the EHR systems of multiple sites and integrate them into one database using EDC software, according to Rogers.

The trial uses a standard backed by the Clinical Data Interchange Standards Consortium and Integrating the Healthcare Enterprise that enables EHR vendors who've adopted the standard to exchange data with EDC vendors who've adopted the same standard.

"What's nice about it is that it integrates data that's already in the medical record, but it also collects new information. It's pre-populating with existing data and collecting new data. It's not just data-mining," Rogers said. "Some of the studies that have been done before are just data-mining where they mine the database and there's no new information entered. This study that we're working on has that component of new information entered."

The advantage of EDC-EHR inoperability, Rogers said, is that it saves clinicians at investigative sites from having to learn a new EDC software for every clinical trial, enabling them to focus on patient care. 

"It's just like using the EHR system that they use every day but it pulls up unique forms that collect data for that clinical trial. Everything looks the same. There's nothing new to learn and it's all within the same workflow that they normally have," he said.

Nextrials is one of three EDC vendors in this space, according to Rogers, and Greenway is one of only a handful of EHR providers to have adopted the standard. Several big pharma companies support the adoption of the standard and have launched their own efforts to support it. Some of the big EDC companies, however, are not yet on board.

"The big EDC vendors are not participating. I think that's because they want to maintain the status quo," Rogers said. "If you're already number one and number two in the industry, you don't want things to change; you want them to stay the same. I think that's why they're cool to this effort."

Although Rogers enjoys being among the first companies to embrace this standard and use it in clinical trials, Rogers hopes to see the number of participating vendors grow. The more sites that adopt the standard, he said, the more clinical studies that will be able to use this technology.

"The collective manpower being put on this is more than any one company could. Having multiple points of view helps us develop a standard that is truly an independent standard that is not skewed toward one company or another," Rogers said. "Yes, we are competitors, but there's a pretty good cooperative spirit on this effort. I think everyone is saving their competitive juices for the marketplace."

Ultimately, however, Rogers does see Nextrials' adoption of the standard as a strategic move for his company.

"We feel that by being one of the first movers it's going to give us a competitive advantage. Down the road, as this movement grows, I think [the big EDC companies] are going to have to join the effort, and they'll be playing catch-up. We see this as a way to gain an early competitive advantage."

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing